Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma	Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, neoplasm, renal cell carcinoma, urinary system disorder	Recruiting	Phase 3	2026-03-17		NCT05738694

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Pfizer	431
ZHOU FANGJIAN	1

8 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Anhui Provincial Hospital	Hefei	China	34
Cancer Hospital Chinese Academy of Medical Sciences	Beijing	China	33
Fudan University Cancer Hospital	Shanghai	China	12
Peking University First Hospital	Beijing	China	72
Sun Yat-Sen University Cancer Center	Guangzhou	China	66
The First Affiliated Hospital of Zhengzhou Hospital	Zhengzhou	China	1
Tianjin Medical University Cancer Institute and Hospital	Tianjin	China	36
West China Hospital	Sichuan	China	3